Press Releases

BIA reacts to proposed IP waiver for COVID-19 vaccines

Steve Bates OBE, Chief Executive of the Bioindustry Association said: “This is not a panacea. Just handing countries governments a recipe book without the ingredients, safeguards, infrastructure, and sizable workforce with the high skills needed to deliver safe and effective vaccines, will not speedily deliver help to all those that need it.

2021 on track to be another record-breaking year for UK biotech investment as investors see returns from the maturing sector

UK biotech companies are on track for a record-breaking year of fundraising according to the latest data released by the UK BioIndustry Association (BIA) and Clarivate. More than £830m in fresh capital was raised in the three months to the end of February, almost topping the £894m raised in the first six months of 2020, which itself was a record-breaking year.

BIA welcomes £1bn investment deal and launch of Life Sciences Investment Programme

Steve Bates OBE, Chief Executive of the BioIndustry Association said: “Congratulations to the Government’s new Office for Investment for securing the £1 billion UAE-UK Sovereign Investment Partnership, which I am delighted to see focused on the opportunities in UK life sciences.

BIA urges the Government to take a science-based approach to regulation of gene editing and GMOs

The BioIndustry Association (BIA) has urged the Government to adopt a science-based and innovation-friendly regulatory framework for gene editing and genetically modified organisms (GMOs).


Member News

How are companies across the Bruntwood SciTech network improving access to better healthcare, medicines and treatments?

The Bruntwood SciTech network is home to some of the UK’s most pioneering science companies, from small medtech startups and scaleups, all the way through to global life science companies that are uncovering world-leading discoveries, creating new medicines and shaping the future of our healthcare. So who are some of the UK’s most innovative life science businesses at the forefront of helping to create a fairer and healthier world?

The Babraham Research Campus sets out its vision and ambition for its future

Cambridge, 12th May 2021: The Babraham Research Campus’ vision is to be one of the best places in the world for discovery bioscience research and innovation; a leading sustainable ecosystem to start, nurture, scale and grow bioscience business.

Magdalen College seeks Strategic Partner to accelerate development of The Oxford Science Park

Oxford, UK, May 10 2021 – Magdalen College Oxford, owner of The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies, has announced that it is seeking a strategic partner with which to accelerate development of the Park.

Applications invited for Accelerate@Babraham life science start-up competition

Five months, five companies: Life-changing ideas, game-changing support. Accelerate@Babraham, the bio-entrepreneurial incubator initiative founded and developed by the Babraham Research Campus - supported by key industry and investor organisations - opens applications for its 2021/22 cohort today.


BIA blog

BIA reaction to the Queen's Speech

The Government has used the Queen’s Speech to highlight its ambition to lead the world in life sciences as part of its plans for economic recovery from the COVID-19 pandemic on the back of the successful vaccination programme. Improving health, creating jobs and levelling up were other key themes set out as the foundations for the Government’s policy agenda.  

CEO Update | 10 May 2021

Jabbed! a TV documentary telling the inside story of the UK Vaccines Taskforce is on Channel 4 this evening at 10pm. Tune in to see interviews with familiar faces including Kate Bingham and Ian McCubbin. I hope the documentary puts front and centre the early work done by the BIA COVID-19 Vaccine Manufacturing Taskforce as part of the UK’s great vaccine story.

Guest Blog | Will Covid-19 herald a new era for clinical trial research across Europe?

Clinical trials are an essential part of getting new treatments from lab to patient but during the COVID-19 pandemic, trials for treatments outside of COVID-19 had been heavily disrupted. However, in light of all this immediate disruption there have been claims that the swift action taken to produce a vaccine and the adoption of technology could set a positive precedent for the future of clinical trial research.

CEO Update | 26 April 2021

The Government is seeking a Chair for its newly announced  Antiviral Taskforce on COVID-19. Details of the role, along with other exciting opportunities in our sector, are on the sector jobs section of the BIA website.  The new Taskforce’s ambition is to find one or two treatments for COVID-19 this year, either in a capsule or tablet form, that can be taken at home at the moment of first diagnosis.  Today’s story in The Telegraph (£) gives a glimpse at how a pill could be developed in the timeframe.


Our publications

Please find a selection of featured BIA publications below. To see our full publications library, click here

Influencing and shaping our sector | BIA update: October 2019 - January 2020

This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences sector, from October 2019 to January 2020.

Global and growing - UK biotech financing in 2019

New figures published today (Wednesday 22 January 2020) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019.

UK life sciences: Catalysing investment and growth

This updated interim report sets out how the UK life sciences sector is driving investment and growth and makes the case for increased cost-effective public investment in the sector.

BIA biotech manifesto 2019

The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector.